arrow
T

Tobias Engler

University Hospital Tuebingen
H指数:15
被引数:998

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose system

人工智能赋能的乳腺癌诊疗决策支持:一项比较医学专用系统与通用系统的多中心盲法基准研究

2026-07-040
OAAI
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center study

卵巢癌患者整合运动与营养计划的开发与优化:BENITA多中心研究的第I阶段

2025-10-170
OAAI
Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis

早期乳腺癌男性患者辅助内分泌治疗应用的影响:来自一项德国大型真实世界理赔数据分析的结果

2025-10-010
OAAI
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial

在一线化疗期间和之后对卵巢癌患者进行运动和营养干预的研究方案 (BENITA) -一项随机对照试验

2024-11-111
OAAI
Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer - Second interim efficacy analysis of the randomized phase III DETECT V trial

在HER2阳性且激素受体阳性的转移性乳腺癌中省略化疗并添加CDK4/6抑制剂ribociclib——随机III期DETECT V试验的第二次中期疗效分析

2024-09-013
PRE
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patientsda multicenter real-world analysis

sacituzumab govitecan和曲妥珠单抗deruxtecan对转移性乳腺癌患者稳定和活跃的脑转移的疗效a多中心真实世界分析

2024-05-017
OAAI